Alcobra Provides Update on Recent FDA Meeting and Path

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
87
Alcobra Provides Update on Recent FDA Meeting and Path Forward for MDX Clinical Development Program

- Alcobra and FDA agree on review of available data from the Phase 3 MEASURE study in a future NDA submission - Top-line results from the MEASURE study to be reported in the coming weeks - FDA to modify Clinical Hold from Full to Partial to allow the conduct of a Phase I safety study - Management to hold a conference call & webcast today, January 9th at 8:00 a.m. Eastern Time/5:00 a.m. Pacific Time

TEL AVIV, Israel, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq: ADHD ), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, received official minutes from its meeting with the Division of Psychiatry Products of the U.S. Food and Drug Administration (FDA) held in early December 2016. The face-to-face meeting was held to discuss the ongoing Clinical Hold for Metadoxine Extended Release (MDX) and paths to resume human clinical trials with MDX.

The official minutes reflect the FDA’s agreement to review the data collected thus far in Alcobra’s Phase 3 MEASURE Study and consider it in a future NDA submission of MDX for treatment of ADHD. The FDA and Alcobra agreed that such an analysis could provide important information with regard to the effectiveness of MDX, as well as information on its safety and tolerability, allowing a more informed discussion of future development activities, as needed. Alcobra has already begun processing the available MEASURE study data and expects to report top-line results for MEASURE in the coming weeks.

The FDA also agreed to modify the Full Clinical Hold to a Partial Hold, pending review and approval of Alcobra’s proposed protocol for a 6-month, Phase 1 clinical study to directly assess the potential relevance of adverse findings observed in long-term, non-clinical (animal) studies of metadoxine with regard to human exposure. The FDA will review results from this safety study and consider the complete lifting of the Full Clinical Hold currently in place on the MDX programs.

“We are encouraged by this productive meeting with the FDA and the progress made in outlining the development path for a future NDA submission of MDX for treatment of pediatric and adult ADHD,” said Dr. Yaron Daniely, President and CEO of Alcobra. “Our focus now is on analyzing the topline data from MEASURE and working closely with the FDA to resume clinical development activities with the goal of bringing MDX to market for the benefit of patients affected by ADHD or other cognitive disorders.”

Conference Call & Webcast
Date:       Monday, January 9, 2017 @ 8:00a.m. Eastern Time/5:00a.m. Pacific Time
Domestic:       855-469-0611
International:        484-756-4341
Passcode:        48962845
Webcast:       http://www.alcobra-pharma.com/events.cfm  
Replays available through January 23, 2017 
Domestic:   855-859-2056
International:   404-537-3406
Passcode:   48962845
     

Forward Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on Alcobra's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Alcobra could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding the timing of future development activities and clinical studies (if the same are initiated at all and under what circumstances) and the timing and status of the results thereof, whether and when the clinical hold will be lifted and under what conditions, whether and when Alcobra will submit an NDA and whether it will be approved by the FDA and timing of future communications to investors. In addition, historic results of scientific research do not guarantee that the conclusions of future research would suggest similar conclusions or that historic results referred to in this press release would be interpreted similarly in light of additional research or otherwise. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Alcobra's Annual Report on Form 20-F for the fiscal year ended December 31, 2015, filed with the Securities and Exchange Commission (SEC) and in subsequent filings with the SEC. Except as otherwise required by law, Alcobra disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contacts                              Alcobra Investor Relations Debbie Kaye US: 212-890-8964, Intl: +972-3-7299871                              IR@alcobra-pharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 95

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 188

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 164

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 53

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 202

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 149

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading

Top 5 Most Recently Viewed Articles

Essential Guidance to Avoid Contractor Fraud After Disasters

Updated Category News Views 249

Essential Guidance for Consumers: Preventing Contractor Fraud In times of devastating natural disasters, such as those caused by wildfires, consumers often find themselves in vulnerable positions. High winds and dry conditions can lead to situations where homes, businesses, and even schools suffer severe damage. It’s in these challenging times that the threat of...

Continue Reading
Stefan Vinberg: A Visionary Leader in Sustainable Real Estate

Updated Category News Views 60

Stefan Vinberg Achieves Dual Recognition at Prestigious Awards Stefan Vinberg, the respected CEO of Insig AB, has recently received outstanding recognition by winning two significant accolades at the Business Worldwide Magazine CEO Awards. These notable honors are the 'Sustainable Real Estate Leadership Award' and 'Growth Strategy CEO of the Year - Sweden'. This...

Continue Reading
SIME Diagnostics Unveils Breakthrough in Neonatal Lung Testing

Updated Category News Views 344

Introduction to AI in Neonatal Medicine SIME Diagnostics is transforming neonatal care with its innovative approach to evaluating lung maturity in preterm infants. This UK-based medical technology company has recently completed a significant clinical study aimed at addressing respiratory challenges faced by late-preterm newborns. The findings promise not only to enhance...

Continue Reading
Baxter Intl's Q4 Results: Key Takeaways and Insights

Updated Category News Views 164

Understanding Baxter Intl's Q4 Earnings The recent earnings report from Baxter Intl (NYSE: BAX) provides crucial insights for investors and analysts alike. In the fourth quarter, the company revealed some significant insights into its financial health and market performance, prompting a closer examination of what this means for shareholders. Earnings Performance Overview...

Continue Reading
Morgan Stanley Sheds Light on UK Investment Trends

Updated Category News Views 99

Insights on UK Investment Intentions From Morgan Stanley Recently, UK assets have captured significant attention, prompting Morgan Stanley (NYSE: MS) to conduct a survey aimed at understanding investors' views, intentions, and positions regarding these assets. This survey highlights the current sentiment surrounding investments in the UK amid uncertain market conditions....

Continue Reading